Differential gene expression in non‐malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP
暂无分享,去创建一个
Sampsa Hautaniemi | Olli Yli-Harja | Matti Nykter | Outi Monni | M. Nykter | O. Yli-Harja | S. Hautaniemi | O. Monni | S. Meri | M. Karjalainen‐Lindsberg | S. Leppä | S. Hemmer | M. Taskinen | H. Nyman | Sirpa Leppä | Seppo Meri | Marja-Liisa Karjalainen-Lindsberg | Minna Taskinen | Heidi Nyman | Antti Harjunpää | Samuli Hemmer | A. Harjunpää | M. Karjalainen-Lindsberg | Antti Harjunpää
[1] David E. Misek,et al. Inducible Expression of Macrophage Receptor Marco by Dendritic Cells Following Phagocytic Uptake of Dead Cells Uncovered by Oligonucleotide Arrays 1 , 2003, The Journal of Immunology.
[2] K. Yamato,et al. Differential Inhibition of Smad6 and Smad7 on Bone Morphogenetic Protein- and Activin-mediated Growth Arrest and Apoptosis in B Cells* , 1999, The Journal of Biological Chemistry.
[3] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[4] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[5] M. Caligiuri,et al. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] Erik Björck,et al. with follicular lymphoma High expression of cyclin B 1 predicts a favorable outcome in patients , 2004 .
[7] Meri,et al. Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms , 2000, Scandinavian journal of immunology.
[8] E. Jaffe. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[9] R. Rosenquist,et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis , 2005, Modern Pathology.
[10] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[11] Ash A. Alizadeh,et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.
[12] Peter Joosten,et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. , 2005, Blood.
[13] P. Solal-Céligny. Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.
[14] S. Gordon,et al. Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. , 1999, Journal of immunology.
[15] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[16] H. Husson,et al. TGFβ-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation , 2004, Leukemia.
[17] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[18] Hervé Watier,et al. From the bench to the bedside: ways to improve rituximab efficacy. , 2004, Blood.
[19] David Botstein,et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. Czuczman,et al. Concurrent administration of granulocyte colony-stimulating factoror granulocyte-monocyte colony-stimulating factor enhancesthe biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model , 2005, Leukemia & lymphoma.
[21] D. Maloney,et al. Rituximab: mechanism of action and resistance. , 2002, Seminars in oncology.
[22] I. Thesleff,et al. Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages , 1995, Cell.
[23] K. Miyazono,et al. Activation of the p21CIP1/WAF1 promoter by bone morphogenetic protein-2 in mouse B lineage cells , 2001, Oncogene.
[24] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[25] A. Freywald,et al. Ephrin-A1 Induces c-Cbl Phosphorylation and EphA Receptor Down-Regulation in T Cells1 , 2003, The Journal of Immunology.
[26] A. Freywald,et al. Ephrin stimulation modulates T cell chemotaxis , 2002, European journal of immunology.
[27] G. Salles,et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.
[28] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[29] J. Delabie,et al. Ephrin-A1 binding to CD4+ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2. , 2005, Blood.
[30] Donna Neuberg,et al. Center B Cells Using Cdna Arrays Gene Expression Profiling of Follicular Lymphoma and Normal Germinal , 2022 .
[31] L. Staudt,et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.
[32] M. Czuczman,et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] P. Solal-Céligny,et al. Follicular lymphoma international prognostic index , 2006, Blood.
[34] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.